# PIÙ MEDICAL: THE ORDINARY SHAREHOLDERS' MEETING APPROVED THE FINANCIAL STATEMENTS AS OF DECEMBER 31, 2025, AND THE ALLOCATION OF NET INCOME FOR THE YEAR

## CONSOLIDATED FINANCIAL STATEMENTS AS OF DECEMBER 31, 2025 PRESENTED

*Castronno (VA), June 29, 2026* – The Shareholders' Meeting of **Più Medical S.p.A.** ("**Più Medical**" or the "**Company**" or the "**Parent Company"**), company listed on Euronext Growth Milan that develops and manages pharmacies and integrated healthcare services, met today in ordinary session and on first call, approved the financial statements for the year ended December 31, 2025, and reviewed the consolidated financial statements as of December 31, 2025.

As previously announced on May 28, 2026, the individual and consolidated financial results as of December 31, 2025, should be viewed in light of the significant corporate transactions that characterized the fiscal year: the scope of operations of the group headed by Più Medical (the "**Group**") covered only the last quarter of the year, as operations began on October 6, 2025—following the completion of the spin-offs from G.S.M. S.r.l. and La Farmaceutica S.p.A.—and the acquisitions of the three new pharmacies were completed on October 31, 2025.

In order to provide a consistent and comparable representation of the Group's economic and financial performance, pro forma consolidated financial statements have therefore been prepared for illustrative purposes, using valuation criteria consistent with historical data and in compliance with applicable regulations, as if the transactions had hypothetically taken place on January 1, 2025.

According to this presentation, pro forma consolidated revenue as of December 31, 2025, amounted to €26.5 million, up 1.7% from €26.1 million in 2024 (pro forma). *Adjusted* pro forma consolidated EBITDA stands at €3.5 million, with a revenue margin of 13.3%, compared to €3.6 million in the pro forma 2024 figures. Pro forma consolidated net income stands at €0.6 million.

Shareholders' Equity amounted to €37.3 million, compared to €22.6 million as of December 31, 2024 (pro forma), and consolidated net financial debt is *cash positive* at €4.9 million (€11.4 million before IFRS 16), compared to a net debt position of €9.5 million as of December 31, 2024 (pro forma).

The Shareholders' Meeting also reviewed the consolidated financial statements as of December 31, 2025, prepared in accordance with IAS/IFRS international accounting standards.

As of December 31, 2025, the Group reported revenue from sales and services of €6.6 million, EBITDA of €0.3 million, EBIT of €0.1 million, and a net loss for the year of €0.04 million.

## Approval of the financial statements as of December 31, 2025

The ordinary Shareholders' Meeting reviewed and approved Più Medical's financial statements for the fiscal year ended December 31, 2025, prepared in accordance with Italian accounting standards (OIC), which reported a net loss of €0.1 million.

During the 2025 fiscal year, the parent company, Più Medical S.p.A., reported revenues of €1.4 million, EBITDA of €0.1 million, and EBIT of €0.04 million.

The Parent Company's Shareholders' Equity as of December 31, 2025, amounted to €37.7 million, while net financial debt was *cash positive* by €8.6 million, supported by available cash at year-end of €16.4 million, against non-current financial debt of approximately €7.8 million.

## Allocation of the 2025 net income

The Ordinary Shareholders' Meeting resolved to fully offset the net loss for the year ended December 31, 2025, amounting to €111,600, by utilizing an equal amount from the "share premium reserve."

## Filing of documents

The financial statements as of December 31, 2025, are available at the Company's registered office, on the Company's website https://piumedical.com/ in the Investor Relations/Financials section, and on the website https://piumedical.com/, nella sezione Investor Relations/Financials, as well as on the website www.borsaitaliana.it in the Shares/Documents section.

The minutes of the Shareholders' Meeting and the summary of voting results will be made available to the public at the Company's registered office and on the Issuer's website https://piumedical.com/, in the Governance/Shareholders' Meetings section, as well as on the website www.borsaitaliana.it, in the Shares/Documents section, in accordance with the terms and procedures set forth in applicable regulations.

***

This press release is available in the Investor Relations section of the website https://piumedical.com/ and on www.emarketstorage.it.

For the dissemination of regulated information, Più Medical uses the eMarket SDIR circuit (www.emarketstorage.it), managed by Teleborsa S.r.l. - with headquarters in Piazza di Priscilla, 4 - Rome.

***

**CONTACTS**

**Investor Relator**
Fabio Luigi Giordano
Viale Lombardia 62, 21040 Castronno (VA)
+39 0332 896059
investor@piumedical.com

**Euronext Growth Advisor & Specialist**
Banca Investis S.p.A.
Via Broletto, 5, 20121 Milano
+39 0299968127
marco.pelosi@bancainvestis.com

**Media Relations**
Twister Communications Group
Via Valparaiso, 3 - 20144 Milano
Tel. +39 02438114200
piumedical@twistergroup.it

**The Company**
Più Medical is a consolidation platform with a buy-fix-scale model, established in 2025 and focused on the *retail* pharmacy sector in Northern Italy. The Group currently manages a network of 16 pharmacies. The Group's activity focuses on the management and enhancement of local pharmacies through a centralized operating model that integrates industrial, managerial, and commercial expertise. Più Medical is characterized by an approach geared towards efficiency and profitability, based on structured processes, economies of scale, and a governance model capable of supporting future growth.